A new biotech company called Trace Neurosciences has been launched to develop a genetic treatment targeting the UNC13A gene linked to ALS. This new strategy has the potential to treat the majority of ALS patients, as well as those with other brain disorders. The company expects to begin testing its lead drug candidate in clinical trials by early 2026. This development comes after surprise findings by two research teams and a significant venture capital investment. Despite struggles in the ALS therapy field, Trace Neurosciences is optimistic about the potential impact of their therapy on ALS patients and those with related brain disorders.
Source link
ALS treatment biotech started with a ‘fall off your chair’ moment
